𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma

✍ Scribed by Gonzalo Sapisochin; Nicholas Fidelman; John P. Roberts; Francis Y. Yao


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
426 KB
Volume
17
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Mixed hepatocellular cholangiocarcinoma (HCC-CC) and intrahepatic cholangiocarcinoma (I-CC) are increasingly being reported in patients with cirrhosis. The aims of this study were (1) to evaluate the incidence, imaging features, and posttransplant outcomes for patients who underwent transplantation for hepatocellular carcinoma (HCC) and were found to have HCC-CC or I-CC in the explant and (2) to compare the outcomes of these patients with those of controls with HCC who were matched (1:3) by the tumor size and the number of nodules in the explant. In the explant specimens of 10 of 302 patients (3.3%) who underwent liver transplantation (LT) for HCC, mixed HCC-CC or I-CC was identified. There were 4 additional incidental cases of HCC-CC. After a median follow-up period of 32 months, 8 of the 14 patients (57%) suffered from tumor recurrence, and the median disease-free survival time was 8 months. The cumulative risk of tumor recurrence was 40% and 70% at 1 and 5 years, respectively, for these 14 patients. When the 4 incidental cases were excluded, the study group with HCC-CC or I-CC (n ΒΌ 10) had a significantly lower incidence of well-differentiated tumors (11.1% versus 43.3%, P < 0.02) and a higher rate of recurrence (60% versus 16.7%, P ΒΌ 0.008) in comparison with the control group of patients with HCC (n ΒΌ 30). The 1-and 5-year cumulative risks of tumor recurrence were 42% and 65%, respectively, in the study group and 10% and 17%, respectively, in the control group (P < 0.002). The actuarial 1-and 5-year patient survival rates without recurrence were also significantly lower in the study group (79% and 32% in the study group and 90% and 62% in the control group, P < 0.03). Dynamic contrast-enhanced computed tomography or magnetic resonance imaging showed progressive contrast enhancement throughout the arterial and portal venous phases without washout in 8 of the 10 patients. In conclusion, HCC-CC and I-CC are associated with a poor prognosis and a high rate of tumor recurrence after LT, and both tumors exhibit radiographic features that are distinct from those observed with HCC.


πŸ“œ SIMILAR VOLUMES


Hepatitis C virus antibody in patients w
✍ Masahiko Tomimatsu; Noriko Ishiguro; Makiko Taniai; Hiroaki Okuda; Akiko Saito; πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 505 KB

Background. In hepatocellular carcinoma (HCC), a high prevalence of hepatitis C virus antibody (anti-HCV) has been reported, indicating that it may be an important etiologic factor in the pathogenesis of HCC. In this study, the authors investigated the prevalence of anti-HCV in HCC patients, as well

Expression of ABH and lewis blood group
✍ Yoshio Okada; Kenji Jinno; Shousuke Moriwaki; Shigeru Morichika; Shou-Ichiro Tor πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 946 KB

Expression of ABH, Lewis, and sialyl Lea antigens was studied in five combined hepatocellular-cholangiocarcinomas. Formalin-fixed liver tissues were immunostained for those antigens using well-characterized monoclonal antibodies and an avidin-biotin-peroxidase complex (ABC) method. Results were comp

Oral capecitabine for the treatment of h
✍ Yehuda Z. Patt; Manal M. Hassan; Alvaro Aguayo; Ajay K. Nooka; Richard D. Lozano πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 101 KB

## Background: The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma. ## Methods: The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (hcc), cholangiocarcinoma (cca),